Weinberg RA.

The biology of cancer

Garland Science, Taylor & Francis Group, LLC (2007)

Hanahan D, Weinberg RA

The hallmarks of cancer.

Cell 100:57-70 (2000)
DOI:10.1016/S0092-8674(00)81683-9

Grady WM.

Genomic instability and colon cancer.

Cancer Metastasis Rev 23:11-27 (2004)
DOI:10.1023/A:1025861527711

Soreide K, Janssen EA, Soiland H, Korner H, Baak JP.

Microsatellite instability in colorectal cancer.

Br J Surg 93:395-406 (2006)
DOI:10.1002/bjs.5328

Anwar S, Hall C, White J, Deakin M, Farrell W, Elder JB.

Hereditary non-polyposis colorectal cancer: an updated review.

Eur J Surg Oncol 26:635-45 (2000)
DOI:10.1053/ejso.2000.0974

Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y.

Colorectal cancer: genetics of development and metastasis.

J Gastroenterol 41:185-92 (2006)
DOI:10.1007/s00535-006-1801-6

Lynch HT, de la Chapelle A.

Hereditary colorectal cancer.

N Engl J Med 348:919-32 (2003)
DOI:10.1056/NEJMra012242

Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C.

The significance of unstable chromosomes in colorectal cancer.

Nat Rev Cancer 3:695-701 (2003)
DOI:10.1038/nrc1165

Behrens J.

Cadherins and catenins: role in signal transduction and tumor progression.

Cancer Metastasis Rev 18:15-30 (1999)
DOI:10.1023/A:1006200102166

Behrens J.

The role of the Wnt signalling pathway in colorectal tumorigenesis.

Biochem Soc Trans 33:672-5 (2005)
DOI:10.1042/BST0330672

Behrens J, Lustig B.

The Wnt connection to tumorigenesis.

Int J Dev Biol 48:477-87 (2004)
DOI:10.1387/ijdb.041815jb

Polakis P.

The adenomatous polyposis coli (APC) tumor suppressor.

Biochim Biophys Acta 1332:F127-47 (1997)
DOI:10.1016/S0304-419X(97)00008-5

Janssen KP.

Murine models of colorectal cancer: studying the role of oncogenic K-ras.

Cell Mol Life Sci 60:495-506 (2003)
DOI:10.1007/s000180300041

Adjei AA.

Blocking oncogenic Ras signaling for cancer therapy.

J Natl Cancer Inst 93:1062-74 (2001)
DOI:10.1093/jnci/93.14.1062

Arakawa H.

Netrin-1 and its receptors in tumorigenesis.

Nat Rev Cancer 4:978-87 (2004)
DOI:10.1038/nrc1504

Mehlen P, Fearon ER.

Role of the dependence receptor DCC in colorectal cancer pathogenesis.

J Clin Oncol 22:3420-8 (2004)
DOI:10.1200/JCO.2004.02.019

Peltomaki P.

DNA mismatch repair and cancer.

Mutat Res 488:77-85 (2001)
DOI:10.1016/S1383-5742(00)00058-2

Li F, Cao Y, Townsend CM Jr, Ko TC.

TGF-beta signaling in colon cancer cells.

World J Surg 29:306-11 (2005)
DOI:10.1007/s00268-004-7813-6

Roman C, Saha D, Beauchamp R.

TGF-beta and colorectal carcinogenesis.

Microsc Res Tech 52:450-7 (2001)
DOI:10.1002/1097-0029(20010215)52:4<450::AID-JEMT1030>3.0.CO;2-O

Watson AJ.

An overview of apoptosis and the prevention of colorectal cancer.

Crit Rev Oncol Hematol 57:107-21 (2006)
DOI:10.1016/j.critrevonc.2005.06.005

Watson AJ.

Apoptosis and colorectal cancer.

Gut 53:1701-9 (2004)
DOI:10.1136/gut.2004.052704

Houlston RS.

What we could do now: molecular pathology of colorectal cancer.

Mol Pathol 54:206-14 (2001)
DOI:10.1136/mp.54.4.206

Von Hoff D, Evans D, Hruban R (ed).

Pancreatic cancer

Jones and Bartlett publishers (2005)

Niitsu Y, Yokota J (ed).

[Oncogenes and Tumor Suppressor Genes for Medical Oncologist] (In Japanese)

Nankodo (1999)

Bardeesy N, DePinho RA.

Pancreatic cancer biology and genetics.

Nat Rev Cancer 2:897-909 (2002)
DOI:10.1038/nrc949

Bardeesy N, Sharpless NE, DePinho RA, Merlino G.

The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model.

Semin Cancer Biol 11:201-18 (2001)
DOI:10.1006/scbi.2000.0371

Cowgill SM, Muscarella P.

The genetics of pancreatic cancer.

Am J Surg 186:279-86 (2003)
DOI:10.1016/S0002-9610(03)00226-5

Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA.

Genetics and biology of pancreatic ductal adenocarcinoma.

Genes Dev 20:1218-49 (2006)
DOI:10.1101/gad.1415606

Shields JM, Pruitt K, McFall A, Shaub A, Der CJ.

Understanding Ras: 'it ain't over 'til it's over'.

Trends Cell Biol 10:147-54 (2000)
DOI:10.1016/S0962-8924(00)01740-2

Holbro T, Civenni G, Hynes NE.

The ErbB receptors and their role in cancer progression.

Exp Cell Res 284:99-110 (2003)
DOI:10.1016/S0014-4827(02)00099-X

Marmor MD, Skaria KB, Yarden Y.

Signal transduction and oncogenesis by ErbB/HER receptors.

Int J Radiat Oncol Biol Phys 58:903-13 (2004)
DOI:10.1016/j.ijrobp.2003.06.002

DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao S, Freeman JW.

Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines.

Oncogene 22:7781-95 (2003)
DOI:10.1038/sj.onc.1206966

Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K.

Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.

Oncogene 22:319-29 (2003)
DOI:10.1038/sj.onc.1206122

Toyonaga T, Nakano K, Nagano M, Zhao G, Yamaguchi K, Kuroki S, Eguchi T, Chijiiwa K, Tsuneyoshi M, Tanaka M.

Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer.

Cancer Lett 201:107-16 (2003)
DOI:10.1016/S0304-3835(03)00482-8

Schmid RM.

Genetic basis of pancreatic cancer.

Best Pract Res Clin Gastroenterol 16:421-33 (2002)
DOI:10.1053/bega.2002.0316

Elliott RL, Blobe GC.

Role of transforming growth factor Beta in human cancer.

J Clin Oncol 23:2078-93 (2005)
DOI:10.1200/JCO.2005.02.047

Rudkin TM, Foulkes WD.

BRCA2: breaks, mistakes and failed separations.

Trends Mol Med 11:145-8 (2005)
DOI:10.1016/j.molmed.2005.02.003

Venkitaraman AR.

Functions of BRCA1 and BRCA2 in the biological response to DNA damage.

J Cell Sci 114:3591-8 (2001)

Soni D, King JA, Kaye AH, Hovens CM.

Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge.

J Clin Neurosci 12:1-5 (2005)
DOI:10.1016/j.jocn.2004.04.001

Zhu Y, Parada LF.

The molecular and genetic basis of neurological tumours.

Nat Rev Cancer 2:616-26 (2002)
DOI:10.1038/nrc866

Holland EC.

Gliomagenesis: genetic alterations and mouse models.

Nat Rev Genet 2:120-9 (2001)
DOI:10.1038/35052535

Bansal K, Liang ML, Rutka JT.

Molecular biology of human gliomas.

Technol Cancer Res Treat 5:185-94 (2006)
DOI:10.1177/153303460600500302

Tabuchi K (ed).

[Gliomas: Research and therapy] (In Japanese)

Springer-Verlag Tokyo (2006)

Kapoor GS, O'Rourke DM.

Mitogenic signaling cascades in glial tumors.

Neurosurgery 52:1425-34; discussion 1434-5 (2003)
DOI:10.1227/01.NEU.0000065135.28143.39

Hulleman E, Helin K.

Molecular mechanisms in gliomagenesis.

Adv Cancer Res 94:1-27 (2005)
DOI:10.1016/S0065-230X(05)94001-3

Schlessinger J.

Cell signaling by receptor tyrosine kinases.

Cell 103:211-25 (2000)
DOI:10.1016/S0092-8674(00)00114-8

Ng HK, Lam PY.

The molecular genetics of central nervous system tumors.

Pathology 30:196-202 (1998)
DOI:10.1080/00313029800169236

Knobbe CB, Merlo A, Reifenberger G.

Pten signaling in gliomas.

Neuro-oncol 4:196-211 (2002)
DOI:10.1093/neuonc/4.3.196

Kondo T, Ezzat S, Asa SL.

Pathogenetic mechanisms in thyroid follicular-cell neoplasia.

Nat Rev Cancer 6:292-306 (2006)
DOI:10.1038/nrc1836

Chiloeches A, Marais R.

Is BRAF the Achilles' Heel of thyroid cancer?

Clin Cancer Res 12:1661-4 (2006)
DOI:10.1158/1078-0432.CCR-06-0051

Reddi HV, McIver B, Grebe SK, Eberhardt NL

The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis.

Endocrinology 148:932-5 (2007)
DOI:10.1210/en.2006-0926

Santoro M, Melillo RM, Fusco A.

RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.

Eur J Endocrinol 155:645-653 (2006)
DOI:10.1530/eje.1.02289

Pierotti MA, Greco A.

Oncogenic rearrangements of the NTRK1/NGF receptor.

Cancer Lett 232:90-8 (2006)
DOI:10.1016/j.canlet.2005.07.043

Sobrinho-Simoes M, Preto A, Rocha AS, Castro P, Maximo V, Fonseca E, Soares P.

Molecular pathology of well-differentiated thyroid carcinomas.

Virchows Arch 447:787-93 (2005)
DOI:10.1007/s00428-005-0065-5

Gimm O.

Thyroid cancer.

Cancer Lett 163:143-56 (2001)
DOI:10.1016/S0304-3835(00)00697-2

Williams D.

Cancer after nuclear fallout: lessons from the Chernobyl accident.

Nat Rev Cancer 2:543-9 (2002)
DOI:10.1038/nrc845

Steffen B, Muller-Tidow C, Schwable J, Berdel WE, Serve H.

The molecular pathogenesis of acute myeloid leukemia.

Crit Rev Oncol Hematol 56:195-221 (2005)
DOI:10.1016/j.critrevonc.2004.10.012

Tenen DG.

Disruption of differentiation in human cancer: AML shows the way.

Nat Rev Cancer 3:89-101 (2003)
DOI:10.1038/nrc989

Choudhary C, Muller-Tidow C, Berdel WE, Serve H.

Signal transduction of oncogenic Flt3.

Int J Hematol 82:93-9 (2005)
DOI:10.1532/IJH97.05090

Stirewalt DL, Radich JP.

The role of FLT3 in haematopoietic malignancies.

Nat Rev Cancer 3:650-65 (2003)
DOI:10.1038/nrc1169

Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L.

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

Leukemia 20:911-28 (2006)
DOI:10.1038/sj.leu.2404245

Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R.

Normal and oncogenic forms of the receptor tyrosine kinase kit.

Stem Cells 23:16-43 (2005)
DOI:10.1634/stemcells.2004-0117

Lorsbach RB, Downing JR.

The role of the AML1 transcription factor in leukemogenesis.

Int J Hematol 74:258-65 (2001)
DOI:10.1007/BF02982058

Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Bohmer FD, Muller-Tidow C, Berdel WE, Serve H.

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.

Blood 101:3164-73 (2003)
DOI:10.1182/blood-2002-06-1677

Mikesch JH, Steffen B, Berdel WE, Serve H, Muller-Tidow C.

The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia.

Leukemia 21:1638-47 (2007)
DOI:10.1038/sj.leu.2404732

Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N, Buergi U, Tenen DG.

ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.

Blood 107:3330-8 (2006)
DOI:10.1182/blood-2005-07-3068

Ren R.

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.

Nat Rev Cancer 5:172-83 (2005)
DOI:10.1038/nrc1567

Deininger MW, Goldman JM, Melo JV.

The molecular biology of chronic myeloid leukemia.

Blood 96:3343-56 (2000)

Calabretta B, Perrotti D.

The biology of CML blast crisis.

Blood 103:4010-22 (2004)
DOI:10.1182/blood-2003-12-4111

Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM.

The biology of chronic myeloid leukemia.

N Engl J Med 341:164-72 (1999)
DOI:10.1056/NEJM199907153410306

Mitani K.

Molecular mechanisms of leukemogenesis by AML1/EVI-1.

Oncogene 23:4263-9 (2004)
DOI:10.1038/sj.onc.1207777

Dong M, Blobe GC.

Role of transforming growth factor-beta in hematologic malignancies.

Blood 107:4589-96 (2006)
DOI:10.1182/blood-2005-10-4169

Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H.

The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.

Blood 92:4003-12 (1998)

Brusa G, Benvenuti M, Mazzacurati L, Mancini M, Pattacini L, Martinelli G, Barbieri E, Greenberger JS, Baccarani M, Santucci MA.

p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.

Haematologica 88:622-30 (2003)

Baldwin AS.

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

J Clin Invest 107:241-6 (2001)
DOI:10.1172/JCI11991

Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL.

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.

Nat Med 8:1145-52 (2002)
DOI:10.1038/nm759

Tilli CM, Van Steensel MA, Krekels GA, Neumann HA, Ramaekers FC.

Molecular aetiology and pathogenesis of basal cell carcinoma.

Br J Dermatol 152:1108-24 (2005)
DOI:10.1111/j.1365-2133.2005.06587.x

Saldanha G, Fletcher A, Slater DN.

Basal cell carcinoma: a dermatopathological and molecular biological update.

Br J Dermatol 148:195-202 (2003)
DOI:10.1046/j.1365-2133.2003.05151.x

Daya-Grosjean L, Couve-Privat S.

Sonic hedgehog signaling in basal cell carcinomas.

Cancer Lett 225:181-92 (2005)
DOI:10.1016/j.canlet.2004.10.003

Tsai KY, Tsao H.

The genetics of skin cancer.

Am J Med Genet C Semin Med Genet 131C:82-92 (2004)
DOI:10.1002/ajmg.c.30037

Athar M, Tang X, Lee JL, Kopelovich L, Kim AL.

Hedgehog signalling in skin development and cancer.

Exp Dermatol 15:667-77 (2006)
DOI:10.1111/j.1600-0625.2006.00473.x

Rubin AI, Chen EH, Ratner D.

Basal-cell carcinoma.

N Engl J Med 353:2262-9 (2005)
DOI:10.1056/NEJMra044151

Saldanha G.

The Hedgehog signalling pathway and cancer.

J Pathol 193:427-32 (2001)
DOI:10.1002/1096-9896(2000)9999:9999<::AID-PATH815>3.0.CO;2-N

Saldanha G, Ghura V, Potter L, Fletcher A.

Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation.

Br J Dermatol 151:157-64 (2004)
DOI:10.1111/j.1365-2133.2004.06048.x

Pasca di Magliano M, Hebrok M.

Hedgehog signalling in cancer formation and maintenance.

Nat Rev Cancer 3:903-11 (2003)
DOI:10.1038/nrc1229

Reifenberger J, Wolter M, Knobbe CB, Kohler B, Schonicke A, Scharwachter C, Kumar K, Blaschke B, Ruzicka T, Reifenberger G.

Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas.

Br J Dermatol 152:43-51 (2005)
DOI:10.1111/j.1365-2133.2005.06353.x

Cohen MM Jr.

The hedgehog signaling network.

Am J Med Genet A 123:5-28 (2003)
DOI:10.1002/ajmg.a.20495

Yamazaki F, Aragane Y, Kawada A, Tezuka T.

Immunohistochemical detection for nuclear beta-catenin in sporadic basal cell carcinoma.

Br J Dermatol 145:771-7 (2001)
DOI:10.1046/j.1365-2133.2001.04468.x

Erb P, Ji J, Wernli M, Kump E, Glaser A, Buchner SA.

Role of apoptosis in basal cell and squamous cell carcinoma formation.

Immunol Lett 100:68-72 (2005)
DOI:10.1016/j.imlet.2005.06.008

Toftgard R.

Hedgehog signalling in cancer.

Cell Mol Life Sci 57:1720-31 (2000)
DOI:10.1007/PL00000654

Miller AJ, Mihm MC Jr.

Melanoma.

N Engl J Med 355:51-65 (2006)
DOI:10.1056/NEJMra052166

Chin L.

The genetics of malignant melanoma: lessons from mouse and man.

Nat Rev Cancer 3:559-70 (2003)
DOI:10.1038/nrc1145

Takata M, Saida T.

Genetic alterations in melanocytic tumors.

J Dermatol Sci 43:1-10 (2006)
DOI:10.1016/j.jdermsci.2006.05.002

Chudnovsky Y, Khavari PA, Adams AE.

Melanoma genetics and the development of rational therapeutics.

J Clin Invest 115:813-24 (2005)
DOI:10.1172/JCI24808

Merlino G.

Cancer biology: the weakest link?

Nature 436:33-5 (2005)
DOI:10.1038/436033a

Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR.

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.

Nature 436:117-22 (2005)
DOI:10.1038/nature03664

Levy C, Khaled M, Fisher DE.

MITF: master regulator of melanocyte development and melanoma oncogene.

Trends Mol Med 12:406-14 (2006)
DOI:10.1016/j.molmed.2006.07.008

Tsao H, Goel V, Wu H, Yang G, Haluska FG.

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.

J Invest Dermatol 122:337-41 (2004)
DOI:10.1046/j.0022-202X.2004.22243.x

Gruss C, Herlyn M.

Role of cadherins and matrixins in melanoma.

Curr Opin Oncol 13:117-23 (2001)
DOI:10.1097/00001622-200103000-00006

Thompson JF, Scolyer RA, Kefford RF.

Cutaneous melanoma.

Lancet 365:687-701 (2005)
DOI:10.1016/S0140-6736(05)17951-3

Omholt K, Platz A, Kanter L, Ringborg U, Hansson J.

NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.

Clin Cancer Res 9:6483-8 (2003)

Hussein MR.

The TP53 tumor suppressor gene and melanoma tumorigenesis: is there a relationship?

Tumour Biol 25:200-7 (2004)
DOI:10.1159/000081103

Lazar-Molnar E, Hegyesi H, Toth S, Falus A.

Autocrine and paracrine regulation by cytokines and growth factors in melanoma.

Cytokine 12:547-54 (2000)
DOI:10.1006/cyto.1999.0614

Cohen HT, McGovern FJ.

Renal-cell carcinoma.

N Engl J Med 353:2477-90 (2005)
DOI:10.1056/NEJMra043172

Pavlovich CP, Schmidt LS.

Searching for the hereditary causes of renal-cell carcinoma.

Nat Rev Cancer 4:381-93 (2004)
DOI:10.1038/nrc1364

Linehan WM, Walther MM, Zbar B.

The genetic basis of cancer of the kidney.

J Urol 170:2163-72 (2003)
DOI:10.1097/01.ju.0000096060.92397.ed

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF.

Met, metastasis, motility and more.

Nat Rev Mol Cell Biol 4:915-25 (2003)
DOI:10.1038/nrm1261

Kim WY, Kaelin WG.

Role of VHL gene mutation in human cancer.

J Clin Oncol 22:4991-5004 (2004)
DOI:10.1200/JCO.2004.05.061

Sudarshan S, Linehan WM, Neckers L.

HIF and fumarate hydratase in renal cancer.

Br J Cancer 96:403-7 (2007)
DOI:10.1038/sj.bjc.6603547

Sudarshan S, Pinto PA, Neckers L, Linehan WM.

Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.

Nat Clin Pract Urol 4:104-10 (2007)
DOI:10.1038/ncpuro0711

Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, van Kessel AG.

Understanding familial and non-familial renal cell cancer.

Hum Mol Genet 11:2489-98 (2002)
DOI:10.1093/hmg/11.20.2489

Mitra AP, Datar RH, Cote RJ.

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.

J Clin Oncol 24:5552-64 (2006)
DOI:10.1200/JCO.2006.08.2073

Wolff EM, Liang G, Jones PA.

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.

Nat Clin Pract Urol 2:502-10 (2005)
DOI:10.1038/ncpuro0318

Wu XR.

Urothelial tumorigenesis: a tale of divergent pathways.

Nat Rev Cancer 5:713-25 (2005)
DOI:10.1038/nrc1697

Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R.

Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors.

Cancer Res 60:6298-302 (2000)

Bellmunt J, Hussain M, Dinney CP.

Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.

Crit Rev Oncol Hematol 46 Suppl:S85-104 (2003)
DOI:10.1016/S1040-8428(03)00067-2

Sugano K, Kakizoe T.

Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging.

Nat Clin Pract Urol 3:642-52 (2006)
DOI:10.1038/ncpuro0649

Dunn KL, Espino PS, Drobic B, He S, Davie JR.

The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling.

Biochem Cell Biol 83:1-14 (2005)
DOI:10.1139/o04-121

Williams SG, Stein JP.

Molecular pathways in bladder cancer.

Urol Res 32:373-85 (2004)
DOI:10.1007/s00240-003-0345-y

Nelson WG, De Marzo AM, Isaacs WB.

Prostate cancer.

N Engl J Med 349:366-81 (2003)
DOI:10.1056/NEJMra021562

Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC.

The emerging role of the PI3-K-Akt pathway in prostate cancer progression.

Prostate Cancer Prostatic Dis 8:108-18 (2005)
DOI:10.1038/sj.pcan.4500776

Pienta KJ, Bradley D.

Mechanisms underlying the development of androgen-independent prostate cancer.

Clin Cancer Res 12:1665-71 (2006)
DOI:10.1158/1078-0432.CCR-06-0067

Feldman BJ, Feldman D.

The development of androgen-independent prostate cancer.

Nat Rev Cancer 1:34-45 (2001)
DOI:10.1038/35094009

Heinlein CA, Chang C.

Androgen receptor in prostate cancer.

Endocr Rev 25:276-308 (2004)
DOI:10.1210/er.2002-0032

Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP.

Androgen receptor gene and hormonal therapy failure of prostate cancer.

Am J Pathol 152:1-9 (1998)

Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D.

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.

Nat Med 6:703-6 (2000)
DOI:10.1038/76287

Macri E, Loda M.

Role of p27 in prostate carcinogenesis.

Cancer Metastasis Rev 17:337-44 (1998)
DOI:10.1023/A:1006133620914

Steers WD.

5alpha-reductase activity in the prostate.

Urology 58:17-24; discussion 24 (2001)
DOI:10.1016/S0090-4295(01)01299-7

Lin D, Meyer DJ, Ketterer B, Lang NP, Kadlubar FF.

Effects of human and rat glutathione S-transferases on the covalent DNA binding of the N-acetoxy derivatives of heterocyclic amine carcinogens in vitro: a possible mechanism of organ specificity in their carcinogenesis.

Cancer Res 54:4920-6 (1994)

Grimes CA, Jope RS.

The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling.

Prog Neurobiol 65:391-426 (2001)
DOI:10.1016/S0301-0082(01)00011-9

Ryan AJ, Susil B, Jobling TW, Oehler MK.

Endometrial cancer.

Cell Tissue Res 322:53-61 (2005)
DOI:10.1007/s00441-005-1109-5

Lax SF.

Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.

Virchows Arch 444:213-23 (2004)
DOI:10.1007/s00428-003-0947-3

Shiozawa T, Konishi I.

Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.

Int J Clin Oncol 11:13-21 (2006)
DOI:10.1007/s10147-005-0546-1

Hecht JL, Mutter GL.

Molecular and pathologic aspects of endometrial carcinogenesis.

J Clin Oncol 24:4783-91 (2006)
DOI:10.1200/JCO.2006.06.7173

Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P, Prat J.

Molecular pathology of endometrial hyperplasia and carcinoma.

Hum Pathol 32:569-77 (2001)
DOI:10.1053/hupa.2001.25929

Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH.

Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.

J Clin Oncol 22:3126-32 (2004)
DOI:10.1200/JCO.2004.11.154

Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF.

Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.

Cancer Res 55:5693-8 (1995)

Kim D, Chung J.

Akt: versatile mediator of cell survival and beyond.

J Biochem Mol Biol 35:106-15 (2002)
DOI:10.5483/bmbrep.2002.35.1.106

Sanchez-Cespedes M.

Dissecting the genetic alterations involved in lung carcinogenesis.

Lung Cancer 40:111-21 (2003)
DOI:10.1016/S0169-5002(03)00033-3

Kaye FJ.

Molecular biology of lung cancer.

Lung Cancer 34 Suppl 2:S35-41 (2001)
DOI:10.1016/S0169-5002(01)00342-7

Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF.

Apoptosis and lung cancer: a review.

J Cell Biochem 88:885-98 (2003)
DOI:10.1002/jcb.10440

Sartorius UA, Krammer PH.

Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines.

Int J Cancer 97:584-92 (2002)
DOI:10.1002/ijc.10096

Adhikary S, Eilers M.

Transcriptional regulation and transformation by Myc proteins.

Nat Rev Mol Cell Biol 6:635-45 (2005)
DOI:10.1038/nrm1703

Spruck C, Strohmaier H, Watson M, Smith AP, Ryan A, Krek TW, Reed SI.

A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1.

Mol Cell 7:639-50 (2001)
DOI:10.1016/S1097-2765(01)00210-6

Buttery RC, Rintoul RC, Sethi T.

Small cell lung cancer: the importance of the extracellular matrix.

Int J Biochem Cell Biol 36:1154-60 (2004)
DOI:10.1016/S1357-2725(03)00261-9

Yamada KM, Araki M.

Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis.

J Cell Sci 114:2375-82 (2001)

Rintoul RC, Sethi T.

The role of extracellular matrix in small-cell lung cancer.

Lancet Oncol 2:437-42 (2001)
DOI:10.1016/S1470-2045(00)00421-6

Ekedahl J, Joseph B, Grigoriev MY, Muller M, Magnusson C, Lewensohn R, Zhivotovsky B.

Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells.

Exp Cell Res 279:277-90 (2002)
DOI:10.1006/excr.2002.5608

Osada H, Takahashi T.

Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer.

Oncogene 21:7421-34 (2002)
DOI:10.1038/sj.onc.1205802

Yokota J, Nishioka M, Tani M, Kohno T.

Genetic alterations responsible for metastatic phenotypes of lung cancer cells.

Clin Exp Metastasis 20:189-93 (2003)
DOI:10.1023/a:1022978932215

Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS.

K-ras mutations in non-small-cell lung carcinoma: a review.

Clin Lung Cancer 8:30-8 (2006)
DOI:10.3816/CLC.2006.n.030

Pfeifer GP, Dammann R.

Methylation of the tumor suppressor gene RASSF1A in human tumors.

Biochemistry (Mosc) 70:576-83 (2005)
DOI:10.1007/s10541-005-0151-y

Altucci L, Gronemeyer H.

The promise of retinoids to fight against cancer.

Nat Rev Cancer 1:181-93 (2001)
DOI:10.1038/35106036

Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF.

Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas.

J Natl Cancer Inst 92:1303-7 (2000)
DOI:10.1093/jnci/92.16.1303

Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA.

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.

Lung Cancer 41 Suppl 1:S29-42 (2003)
DOI:10.1016/S0169-5002(03)00137-5

Panani AD, Roussos C.

Cytogenetic and molecular aspects of lung cancer.

Cancer Lett 239:1-9 (2006)
DOI:10.1016/j.canlet.2005.06.030

Mitsuuchi Y, Testa JR.

Cytogenetics and molecular genetics of lung cancer.

Am J Med Genet 115:183-8 (2002)
DOI:10.1002/ajmg.10692

Breuer RH, Postmus PE, Smit EF.

Molecular pathology of non-small-cell lung cancer.

Respiration 72:313-30 (2005)
DOI:10.1159/000085376

Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Heimburger DC, Grizzle WE.

Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung.

Clin Cancer Res 8:734-44 (2002)

Awaya H, Takeshima Y, Furonaka O, Kohno N, Inai K.

Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.

J Clin Pathol 58:1076-80 (2005)
DOI:10.1136/jcp.2004.025585

Lappano R, Maggiolini M

G protein-coupled receptors: novel targets for drug discovery in cancer.

Nat Rev Drug Discov 10:47-60 (2011)
DOI:10.1038/nrd3320

O'Hayre M, Degese MS, Gutkind JS

Novel insights into G protein and G protein-coupled receptor signaling in cancer.

Curr Opin Cell Biol 27:126-35 (2014)
DOI:10.1016/j.ceb.2014.01.005

Dorsam RT, Gutkind JS

G-protein-coupled receptors and cancer.

Nat Rev Cancer 7:79-94 (2007)
DOI:10.1038/nrc2069